OR22-1 Liraglutide as Add-on to SGLT2 Inhibitors in Patients with Inadequately Controlled Type 2 Diabetes (LIRA-ADD2SGLT2i): A 26-Week, Randomized, Double-Blind, Placebo-Controlled Trial

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) reduce glycated hemoglobin (HbA(1c)), but randomized controlled trial data on their combined use are limited. The LIRA-ADD2SGLT2i trial compared the effect on glycemic control of liraglutide...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Endocr Soc
Autors principals: Blonde, Lawrence, Belousova, Lidia, Fainberg, Udi, Garcia-Hernandez, Pedro, Jain, Sunil, Kaltoft, Margit, Mosenzon, Ofri, Nafach, Jalal, Palle, Mads, Réa, Rosangela
Format: Artigo
Idioma:Inglês
Publicat: Endocrine Society 2019
Matèries:
Diabetes Mellitus and Glucose Metabolism
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6554790/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-OR22-1
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars